OMCM Omnicomm Systems Inc.

OmniComm Systems to be acquired by Anju Software

OmniComm Systems to be acquired by Anju Software

FORT LAUDERDALE, Fla., July 16, 2019 (GLOBE NEWSWIRE) -- OmniComm Systems, Inc. (OTCQX: OMCM) (“OmniComm”), a leading strategic software solutions provider to the life sciences industry, announced today that it has entered into a merger agreement with Anju Software, Inc. (“Anju”). Under the terms of the agreement, OmniComm will become a wholly owned subsidiary of Anju. Upon closing, shares of OmniComm common stock will be cancelled and automatically converted into the right to receive $0.41032 per share, without interest, representing an 58% premium to the closing price on July 15, 2019.

Anju is a provider of data and application software to life sciences companies, contract research organizations, and medical device manufacturers. Anju’s software aides in workflow management, data collection, communications management, and decision-making processes throughout the life sciences value chain. The merger of OmniComm and Anju positions the combined organization as a leader in the eClinical solutions market, with particular expertise in electronic data capture and eSource. OmniComm’s solutions, including its flagship TrialMaster® and TrialOne® products, will complement Anju’s existing solution suite.

“Our merger with Anju represents the next chapter in OmniComm’s evolution, starting as a systems integrations company and growing into a global provider of software and services for the Life Sciences community,” commented Randall Smith, Founder and Executive Vice Chairman of OmniComm. “OmniComm will help bolster Anju’s current product portfolio and we believe that Anju’s customer base will embrace OmniComm’s eClinical solutions, helping to accelerate growth.”

Stockholders of OmniComm holding  at least a majority of the outstanding shares of voting stock have approved the merger agreement by written consent, and the closing is expected to occur by October 31, 2019 following the satisfaction of customary closing conditions.

Crosstree Capital Securities, LLC (“Crosstree”) served as OmniComm’s financial advisor and Foley & Lardner LLP served as OmniComm’s legal counsel in the transaction. Madison Park Group LLC served as Anju’s financial advisor and Snell & Wilmer LLP served as Anju’s legal counsel in the transaction.

About OmniComm Systems, Inc.

OmniComm is a healthcare technology company that provides web-based electronic data capture and eClinical solutions and related value-added services to pharmaceutical and biotech companies, contract research organizations, and other clinical trial sponsors principally located in the United States, Europe, and East Asia. OmniComm’s proprietary EDC and eClinical software applications – TrialMaster®, TrialOne®, eClinical Suite, Promasys®, IRTMaster, AutoEncoder, and Acuity – allow clinical trial sponsors and investigative sites to securely collect, validate, transmit, and analyze clinical trial data. OmniComm is headquartered in Fort Lauderdale, FL.

For more information about OmniComm, visit

About Anju Software, Inc.

Anju Software, Inc. is a leading provider of comprehensive software solutions to the life sciences industry that provides an integrated platform spanning clinical operations, medical affairs, and commercial divisions, including integrated data intelligence. Anju has combined deep industry and software domain expertise to build a next generation platform for the life sciences sector that can scale to provide solutions that meet customers’ needs from “molecule to retirement.” Anju provides end-to-end software solutions that help customers manage mission-critical pharma processes and turn data into actionable insights. Anju solutions are used by large and small pharmaceutical companies, contract research organizations, full service agencies, and medical device companies. Anju is headquartered in Tempe, AZ.

For more information about Anju, visit

Cautionary Note Regarding Forward-Looking Statements

            This announcement contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning OmniComm Systems, Inc.  These statements include, but are not limited to, statements regarding the expected completion of the merger, expected benefits and costs of the merger, management plans relating to the merger, and other statements identified by words such as “will,” “expect,” “believe,” “anticipate,” “estimate,” “should,” “intend,” “plan,” “potential,” “predict,” “project,” “aim,” and similar words, phrases, or expressions.  These forward-looking statements are based on current expectations and beliefs of the management of OmniComm and Anju (as the case may be), as well as assumptions made by, and information currently available to, such management, current market trends, and market conditions and involve risks and uncertainties, many of which are outside of each company’s and each company’s management’s control, and which may cause actual results to differ materially from those contained in forward-looking statements.  Accordingly, you should not place undue reliance on such statements.

Those risks, uncertainties, and assumptions include: the risk that the merger may not be completed in a timely manner, or at all, which may adversely affect OmniComm’s business and the price of the OmniComm’s common stock; the failure to satisfy any of the conditions to the consummation of the merger; the effect of the announcement or pendency of the merger on OmniComm’s business relationships, operating results, and business generally; risks that the merger disrupts current plans and operations and the potential difficulties in employee retention as a result of the merger; risks related to diverting management’s attention from ongoing business operations; the outcome of any legal proceedings that may be instituted related to the merger; unexpected costs, charges, or expenses resulting from the merger; and other risks described in OmniComm’s filings with the United States Securities and Exchange Commission, such as Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K.

            Forward-looking statements speak only as of the date of this communication.  OmniComm does not undertake any intent or obligation to publicly update or revise any of the estimates and other forward-looking statements made in this announcement, whether as a result of new information, future events, or otherwise, except as required by law.

OmniComm Systems, Inc.
Phone: +1.954.473.1254
EN
16/07/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Omnicomm Systems Inc.

 PRESS RELEASE

Anju Software announces appointment of new CMO to support and sustain ...

Anju Software announces appointment of new CMO to support and sustain rapid growth TEMPE, Ariz., March 16, 2020 (GLOBE NEWSWIRE) -- Anju Software announced today that Bill Leander has joined its executive leadership team as Chief Marketing Officer (CMO). As CMO, Mr. Leander’s focus will be on further accelerating growth by strengthening Anju’s marketing capabilities, advancing product management disciplines, and communicating the proven power of products to the life sciences market. To quote Bill, “Anju has a wealth of technology and products that meet mission-critical needs of the organi...

 PRESS RELEASE

Sofpromed CRO Adopts OmniComm’s TrialMaster® as EDC Solution for Cl...

Sofpromed CRO Adopts OmniComm’s TrialMaster® as EDC Solution for Clinical Trials in Oncology Spain-based, oncology-focused CRO will use TrialMaster EDC to support clinical data management services for sponsors in the oncology sector, particularly in phase I-IV cancer trials FORT LAUDERDALE, FLA., Dec. 16, 2019 (GLOBE NEWSWIRE) -- Sofpromed, a European full service contract research organization (CRO) specializing in the integral management of phase I-IV clinical trials in oncology, has selected TrialMaster as their preferred electronic data capture (EDC) system to support their clinical...

 PRESS RELEASE

FGK Clinical Research Signs Five-Year Agreement with OmniComm Systems ...

FGK Clinical Research Signs Five-Year Agreement with OmniComm Systems for Multiple eClinical Products FORT LAUDERDALE, Fla., Dec. 02, 2019 (GLOBE NEWSWIRE) -- FGK Clinical Research GmbH (FGK), a European, full-service contract research organization has entered into a multi-year partnership with OmniComm Systems, Inc., an Anju Software company and a leading global provider of patient-centric, clinical data management technology. Under the terms of the agreement, FGK will use TrialMaster® electronic data capture (EDC), IRTMaster (web-based self-service clinical supply management and randomi...

 PRESS RELEASE

OmniComm Systems Releases IRTMaster Version 5.2, a Customizable Intera...

OmniComm Systems Releases IRTMaster Version 5.2, a Customizable Interactive Response Technology System for Streamlined Clinical Trial and Supply Management OmniComm’s IRTMaster Features Configurable, Pre-Validated Modules to Accelerate Trial Development FORT LAUDERDALE, Fla., Nov. 25, 2019 (GLOBE NEWSWIRE) --  OmniComm Systems, Inc., an Anju Software Company and leading strategic software solutions provider to the life sciences industry, announced today its release of IRTMaster Version 5.2, an enhanced product offering to complement their comprehensive eClinical suite. IRTMaster is a f...

 PRESS RELEASE

OmniComm Systems and snapIoT to Showcase Virtual/Decentralized Trials ...

OmniComm Systems and snapIoT to Showcase Virtual/Decentralized Trials Technology at SCDM 2019 FORT LAUDERDALE, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Virtual or decentralized clinical trials — named one of the year’s by Forbes magazine — will claim center stage at the annual conference of the Society of Clinical Data Management (SCDM), Sept. 29-Oct. 2, in Baltimore, MD. At the event, OmniComm Systems and snapIoT will demonstrate how their respective eClinical solutions enable virtual/decentralized trials. The two companies will show how ePRO, eCOA, eConsent and other innovations can facilita...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch